ClinicalTrials.gg
CompletedNCT05638854Updated Sep 4, 2026

A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis

A Phase 1 interventional study of ZB002 and Placebo in Healthy Volunteers and Rheumatoid Arthritis, sponsored by Zenas BioPharma (USA), LLC. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Zenas BioPharma (USA), LLC · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.

Enrollment
118th of 140
72 · median 469
Started
2022
with 1 other
Phase 1
21 of 154
12 open now
Registered
135th of 154
by date

Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 118th largest by enrollment of the 140 interventional ones that give a count, is one of 2 that started in 2022, is one of 21 in phase 1, and was the 135th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Australia, or all of them as a file.
02

Study summary

This double-blind, randomized, placebo-controlled study will assess the safety and pharmacokinetics of ZB002 in healthy participants and in participants with rheumatoid arthritis (RA). The study consists of 2 parts. Part A: Single Ascending Dose (SAD), which will include only healthy volunteers. Part B: Multiple Ascending Dose (MAD), will commence after completion of the SAD study and will include RA participants.

Read the detailed description

Part A (SAD): Up to approximately 48 healthy volunteers across 6 cohorts randomized to receive ZB002 or placebo as a single dose.

Part B (MAD): Up to approximately 24 participants with RA across 3 cohorts randomized to receive ZB002 or placebo as multiple doses.

03

Conditions studied

  • Healthy Volunteers
  • Rheumatoid Arthritis

Keywords

  • Healthy Volunteers
  • Healthy Subjects
  • Healthy Participants
  • Patients
  • Rheumatoid Arthritis
  • RA
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria

Part A SAD (HV):

  • Healthy male or female participants 18 to 55 years of age.
  • Body weight ≥ 50 kg for male participants and ≥ 45 kg for female participants; of 18 to 35 kg/m\^2 for both male and female participants.
  • Considered in good health as determined by the Investigator.
  • Female participants of must agree to abstinence or use an effective form of .
  • Male participants must be surgically sterile or agree to use effective contraception.
  • Willing and able to understand the characteristics and purposes of the study, including possible risks involved, and willing to comply with all the study requirements and provide written for the study.

Part B MAD (RA Participants):

  • Male or female participants 18 to 70 years (inclusive) of age at Screening.
  • Body mass index of ≥ 18.0 and ≤ 40.0 kg/m2.
  • Diagnosis of RA and meeting the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism classification criteria for RA ≥ 3 months before Screening.
  • Use of methotrexate at 7.5 to 25 mg/week for ≥ 3 months, with stable dosing for ≥ 4 weeks, before randomization. Hydroxychloroquine/chloroquine and/or sulfasalazine are allowed if started ≥ 3 months before randomization and a stable dose is maintained after the Screening Visit.

Main Exclusion Criteria

Part A SAD (HV):

  • Surgery within 4 weeks before Screening or planned surgery during the clinical study.
  • Use of prescription medications, biological products, or other medicines within 2 weeks before Study Day 1 or 5 half-lives of the product, whichever is greater. Use of over-the-counter medications or vitamins/dietary supplements within 7 days of dosing unless considered by the Investigator to not pose a risk or impact the study results.
  • Treatment with any drug within 30 days or 5 half-lives, whichever is greater, before the first dose of the study drug, or currently enrolled in another clinical study.
  • abnormality.
  • Positive for infection, active , or .
  • Positive for COVID-19 virus.
  • Positive QuantiFERON®-TB Gold or T-SPOT® test for Mycobacterium tuberculosis.
  • Bacteria, viruses, systemic fungi, parasites, or other opportunistic infections within 30 days before Study Day 1.
  • Documented history of drug abuse in the previous 12 months before Screening, or positive for urine drug screen on Screening and/or Day -1.
  • Donated blood (including component blood) or lost > 400 mL within 3 months before Screening or received a transfusion within 3 months of Screening.
  • History of relevant allergies (including allergy to any murine or human-derived protein or immunoglobulin products, rubber or latex, or other allergies that in the opinion of the Investigator make inclusion in the study inappropriate).
  • Average daily smoking > 10 cigarettes or cigarette equivalents per day within 6 months of Screening.
  • Consume > 14 standard units of alcohol per week (1 standard unit is equivalent to approximately 360 mL of beer, 45 mL of spirits with 40% alcohol, or 150 mL of wine) or a positive alcohol breath test on Day -1.

Part B MAD (RA Participants):

  • Inflammatory joint disease other than RA. Note: Current diagnosis of secondary Sjogren's Syndrome is permitted.
  • Surgery within 4 weeks before Screening or planned surgery during the clinical study.
  • History of any within 5 years, except for successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix.
  • Documented history of drug abuse in the previous 12 months before Screening (Days -28 to -1), or positive for urine drug screen for nonprescribed drugs other than cannabinoid at Screening.
  • Any condition considered by the investigator to make participation in the study inappropriate.
  • Donated blood (including component blood) or lost > 400 mL within 1 month before Screening or received a transfusion within 3 months of Screening.
  • After the Screening Visit, use > 10 mg/day (prednisone equivalent) or increase in dose
  • Positive for HIV infection, active hepatitis C, or hepatitis B.
  • Test positive for Mycobacterium tuberculosis.
  • Bacterial, viral, systemic fungal, parasitic, or opportunistic infection not resolved at least 14 days before Study Day 1 or expected to be treated with antibiotics during the Treatment Period, or history of recurrent infections.
  • Employees or related personnel of the study site, the sponsor, or contract research organization.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Part A: SAD in Healthy Volunteers

    Healthy volunteers will receive a single dose of ZB002 or placebo

    Drug: ZB002 · Drug: Placebo

  • Experimental
    Part B: MAD in RA Participants

    RA participants will receive ZB002 or placebo every 4 weeks (Q4W) × 3 administrations

    Drug: ZB002 · Drug: Placebo

Interventions

  • DrugZB002

    ZB002 will be administered subcutaneously as per schedule specified in the respective arm.

  • DrugPlacebo

    Placebo will be administered subcutaneously as per schedule specified in the respective arm.

  • DrugZB002

    ZB002 will be administered subcutaneously as per schedule specified in the respective arm.

  • DrugPlacebo

    Placebo will be administered subcutaneously as per schedule specified in the respective arm.

06

What researchers measure

Primary outcomes

  1. Part A: Safety and Tolerability in HVs

    To evaluate the safety and tolerability of ZB002 in HVs by assessing the number, severity and type of adverse events, including changes in laboratory safety test and electrocardiogram (ECG)

    Time frame: Day 1 through Day 120

  2. Part B: Safety and Tolerability of multiple doses of ZB002 in participants with RA

    To evaluate the safety and tolerability of ZB002 in participants with RA by assessing the number of participants with Treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAE leading to discontinuation

    Time frame: Day 1 through Day 176

Secondary outcomes

  1. Part A: Maximum observed serum concentration (Cmax)

    Pharmacokinetics

    Time frame: Day 1 through Day 120

  2. Part A: Time for Cmax (Tmax)

    Pharmacokinetics

    Time frame: Day 1 through Day 120

  3. Part A: Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)

    Pharmacokinetics

    Time frame: Day 1 through Day 120

  4. Part A: AUC from time 0 to the last quantifiable concentration (AUClast)

    Pharmacokinetics

    Time frame: Day 1 through Day 120

  5. Part A: Terminal half-life (t1/2)

    Pharmacokinetics

    Time frame: Day 1 through Day 120

  6. Part A: Apparent clearance following extravascular dosing (CL/F)

    Pharmacokinetics

    Time frame: Day 1 through Day 120

  7. Part A: Apparent volume of distribution following extravascular administration (Vz/F)

    Pharmacokinetics

    Time frame: Day 1 through Day 120

  8. Part B (All Doses): Serum trough concentration (Ctrough)

    Before repeat-dose administration (or at the end of the dosing interval \[tau\] after the final dose)

    Time frame: Day 1 through Day 176

  9. Part B (Doses 1 and 3): Maximum observed serum concentration (Cmax)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  10. Part B (Doses 1 and 3): Time for Cmax (Tmax)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  11. Part B (Doses 1 and 3): AUC over the dosing interval, tau (AUCtau)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  12. Part B (Doses 1 and 3): Accumulation ratio of Cmax (ARCmax)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  13. Part B (Doses 1 and 3): Accumulation ratio of AUC (ARAUC)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  14. Part B (Dose 3 only): Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  15. Part B (Dose 3 only): Terminal half-life (t1/2)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  16. Part B (Dose 3 only): AUC from time 0 to the last quantifiable concentration (AUClast)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  17. Part B (Dose 3 only): Apparent clearance following extravascular dosing (CL/F)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  18. Part B (Dose 3 only): Apparent volume of distribution following extravascular (Vz/F)

    Pharmacokinetics

    Time frame: Day 1 through Day 176

  19. Part B: Serum anti-ZB002 antibody prevalence and incidence

    Time frame: Day 1 through Day 176

  20. Part B: Cytokine/chemokine secretion in ex vivo stimulated whole blood

    Pharmacodynamic

    Time frame: Day 1 through Day 176

07

Study locations

2 sites
  • Veritus Research
    Melbourne, Australia
  • NZCR New Zealand Clinical Research
    Christchurch, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Feb 2026, 38 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 38 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2022
First posted
Dec 6, 2022
StartActual
Dec 8, 2022
Primary completionActual
Feb 16, 2026
CompletionActual
Feb 16, 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05638854
Lead sponsor
Zenas BioPharma (USA), LLC
Responsible party
Sponsor
First posted
Dec 6, 2022
Start date
Dec 8, 2022
Primary completion
Feb 16, 2026
Completion
Feb 16, 2026
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion